An interventional study of Akkermansia Supplement and Placebo Supplement in Obesity & Overweight, sponsored by Second Affiliated Hospital of Nanchang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Second Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Treatment
Overweight and obesity are common metabolic disorders associated with increased risks of diabetes, cardiovascular disease, and other health problems. The gut microbiota plays an important role in regulating metabolism, inflammation, and intestinal health. Akkermansia, a beneficial gut bacterium, has been associated with metabolic health and may have potential benefits for weight management.
This study aims to investigate the relationship between gut microbiota characteristics and overweight or obesity and to evaluate the efficacy and safety of Akkermansia supplementation in individuals with overweight or obesity.
The study consists of two stages. The first stage is an observational study comparing gut microbiota characteristics between healthy individuals and individuals with overweight or obesity. The second stage is a randomized, double-blind, placebo-controlled clinical trial in which eligible participants with overweight or obesity will receive either Akkermansia supplementation or placebo once daily for 12 weeks, followed by follow-up through Week 24.
The study will evaluate changes in body weight, metabolic health, gut microbiota characteristics, related metabolites, and safety outcomes. The findings may provide clinical evidence regarding the potential use of Akkermansia supplementation for the management of overweight and obesity.
This is a prospective, two-stage clinical study investigating the relationships among Akkermansia, gut microbiota characteristics, and overweight or obesity, and evaluating the efficacy and safety of Akkermansia supplementation in individuals with overweight or obesity.
The first stage is a cross-sectional observational study designed to compare gut microbiota characteristics between healthy controls and participants with overweight or obesity. This stage will evaluate differences in gut microbiota composition and explore associations between Akkermansia abundance, metabolic characteristics, and related clinical parameters. Participants with overweight or obesity who meet the eligibility criteria and are willing to provide additional informed consent may proceed to the second-stage randomized controlled trial.
The second stage is a randomized, double-blind, placebo-controlled clinical trial. Eligible participants with overweight or obesity will be randomly assigned to receive either Akkermansia supplementation or placebo. Participants in the Akkermansia group will receive oral Akkermansia supplementation once daily for 12 weeks, while participants in the placebo group will receive an identical placebo. All participants will receive standardized lifestyle guidance throughout the intervention period and will be followed through Week 24 to evaluate treatment effects and safety.
The primary objective of the intervention stage is to evaluate whether Akkermansia supplementation improves body weight outcomes compared with placebo. Secondary evaluations will include changes in anthropometric measurements, glucose and lipid metabolism parameters, inflammatory and gut barrier-related biomarkers, gut microbiota composition, gut microbiota-related and blood metabolites, appetite-related hormones, psychological status, gastrointestinal tolerance, and safety outcomes.
The total planned enrollment represents the number of unique participants rather than the sum of participants across the two study stages. Participants enrolled in the first observational stage may proceed to the randomized controlled trial if they meet the eligibility criteria and are willing to participate. Additional participants may be recruited to achieve the planned sample size for the randomized controlled trial.
This study will further explore the potential relationships among Akkermansia supplementation, gut microbiota regulation, metabolic improvement, and clinical outcomes in individuals with overweight or obesity. The findings may provide clinical evidence to support the development of microbiota-based strategies for weight management.
6,583 studies on the registry are indexed under Obesity; 1,718 are open to participants now.
This study's planned enrollment of 150 is above the median of 77 across 5,091 interventional studies indexed under Obesity.
Browse Obesity studies →Second Affiliated Hospital of Nanchang University is the lead sponsor of 82 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
This study includes healthy controls and participants with overweight or obesity. Eligibility criteria are as follows:
Inclusion Criteria:
Healthy Controls:
Overweight/Obese Participants:
Exclusion Criteria:
Participants with overweight or obesity will receive oral Akkermansia supplementation once daily for 12 weeks. The intervention aims to evaluate the effects of Akkermansia supplementation on body weight, metabolic parameters, gut microbiota characteristics, related metabolites, and safety outcomes. Participants will be followed through Week 24 to assess treatment effects and safety.
Dietary Supplement: Akkermansia Supplement
Participants with overweight or obesity will receive a placebo once daily for 12 weeks. The placebo will have an appearance, color, odor, packaging, and administration method identical to those of the Akkermansia supplement. Participants will be followed through Week 24 to assess treatment effects and safety.
Dietary Supplement: Placebo Supplement
Akkermansia supplementation will be administered orally once daily for 12 weeks to participants with overweight or obesity. All participants will receive standardized lifestyle guidance throughout the intervention period. Treatment effects and safety will be assessed through Week 24.
The placebo will be administered orally once daily for 12 weeks to participants with overweight or obesity. It will be identical to the Akkermansia supplement in appearance, color, odor, packaging, and administration method. All participants will receive standardized lifestyle guidance throughout the intervention period. Treatment effects and safety will be assessed through Week 24.
Percentage Change in Body Weight from Baseline at Week 12
Percentage change in body weight from baseline to Week 12, calculated as \[(body weight at Week 12 - body weight at baseline) / body weight at baseline\] × 100. The percentage change will be compared between the Akkermansia supplementation group and the placebo group.
Time frame: Baseline and Week 12
Change in Body Mass Index from Baseline
Change in body mass index (BMI), calculated as body weight in kilograms divided by height in meters squared, from baseline to each follow-up visit. Results will be reported in kg/m².
Time frame: Baseline, Weeks 4, 8, 12, 18, and 24.
Change in Waist Circumference from Baseline
Change in waist circumference from baseline at each follow-up visit. Waist circumference will be measured using the standardized study procedure and reported in centimeters.
Time frame: Baseline, Weeks 4, 8, 12, 18, and 24.
Change in Body Fat Percentage from Baseline
Change in body fat percentage from baseline, measured using the body composition assessment method specified in the study protocol. Results will be reported as percentage points.
Time frame: Baseline, Weeks 12 and 24.
Change in Fasting Blood Glucose from Baseline
Change in fasting blood glucose concentration from baseline. Blood samples will be collected after the fasting period specified in the study protocol. Results will be reported in the laboratory's standard concentration unit.
Time frame: Baseline, Weeks 12 and 24.
Change in Glycated Hemoglobin from Baseline
Change in glycated hemoglobin (HbA1c) from baseline. Results will be reported as a percentage or in mmol/mol, according to the laboratory method.
Time frame: Baseline, Weeks 12 and 24.
Change in Homeostatic Model Assessment of Insulin Resistance from Baseline
Change in the homeostatic model assessment of insulin resistance (HOMA-IR) from baseline. HOMA-IR will be calculated using fasting glucose and fasting insulin according to the prespecified study method and reported as a dimensionless index.
Time frame: Baseline, Weeks 12 and 24.
Change in Total Cholesterol from Baseline
Change in serum total cholesterol concentration from baseline. Results will be reported in the laboratory's standard concentration unit.
Time frame: Baseline, Weeks 12 and 24.
Change in Triglyceride Concentration from Baseline
Change in serum triglyceride concentration from baseline. Results will be reported in the laboratory's standard concentration unit.
Time frame: Baseline, Weeks 12 and 24.
Change in Low-Density Lipoprotein Cholesterol from Baseline
Change in low-density lipoprotein cholesterol (LDL-C) concentration from baseline. Results will be reported in the laboratory's standard concentration unit.
Time frame: Baseline, Weeks 12 and 24.
Change in High-Density Lipoprotein Cholesterol from Baseline
Change in high-density lipoprotein cholesterol (HDL-C) concentration from baseline. Results will be reported in the laboratory's standard concentration unit.
Time frame: Baseline, Weeks 12 and 24.
Change in Alanine Aminotransferase from Baseline
Change in serum alanine aminotransferase (ALT) activity from baseline. Results will be reported in U/L.
Time frame: Baseline, Weeks 12 and 24.
Change in Aspartate Aminotransferase Activity from Baseline
Change in serum aspartate aminotransferase (AST) activity from baseline, calculated as the AST activity at the follow-up visit minus the AST activity at baseline. Results will be reported in units per liter (U/L).
Time frame: Baseline, Weeks 12 and 24.
Change in Serum Creatinine from Baseline
Change in serum creatinine concentration from baseline. Results will be reported in the laboratory's standard concentration unit.
Time frame: Baseline, Weeks 12 and 24.
Change in High-Sensitivity C-Reactive Protein from Baseline
Change in high-sensitivity C-reactive protein (hs-CRP) concentration from baseline. Results will be reported in the laboratory's standard concentration unit.
Time frame: Baseline, Weeks 12 and 24.
Change in Interleukin-1β Concentration from Baseline
Change in interleukin-1β (IL-1β) concentration from baseline. Results will be reported in the laboratory's standard concentration unit.
Time frame: Baseline, Weeks 12 and 24.
Change in Relative Abundance of Akkermansia from Baseline
Change in the relative abundance of Akkermansia in fecal samples from baseline, determined using the prespecified gut microbiota analysis method. Results will be reported as relative abundance using the same analytical method at each assessment.
Time frame: Baseline, Weeks 12 and 24.
Changes in Fecal Gut Microbiota Composition Assessed by Microbiome Sequencing
Changes from baseline in fecal gut microbiota composition assessed by microbiome sequencing. The analysis will characterize the relative abundance of bacterial taxa and identify differences in gut microbial composition between the Akkermansia supplementation group and the placebo group. Relative abundance will be reported for the prespecified microbial taxa using the same sequencing and bioinformatics procedures at each assessment.
Time frame: Baseline, Weeks 12 and 24.
Change in Generalized Anxiety Disorder-7 Total Score from Baseline
Change in the total score on the Generalized Anxiety Disorder-7 (GAD-7) questionnaire from baseline. The total score ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms.
Time frame: Baseline, Weeks 12 and 24.
Change in Patient Health Questionnaire-9 Total Score from Baseline
Change in the total score on the Patient Health Questionnaire-9 (PHQ-9) from baseline. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.
Time frame: Baseline, Weeks 12 and 24.
Change in Pittsburgh Sleep Quality Index Global Score from Baseline
Change in the global score on the Pittsburgh Sleep Quality Index (PSQI) from baseline. The standard global score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Time frame: Baseline, Weeks 12 and 24.
Number of Participants with Gastrointestinal Adverse Events
Number and percentage of participants experiencing at least one gastrointestinal adverse event during the study, including diarrhea, constipation, nausea, vomiting, abdominal pain, or abdominal distension. Events will be recorded and classified according to the study's adverse event assessment procedures.
Time frame: From initiation of the intervention through Week 24.
Changes in Fecal Metabolite Profiles Assessed by Metabolomics
Changes from baseline in fecal metabolite profiles assessed by metabolomics analysis. Prespecified fecal metabolites will be identified and quantified where applicable. Individual metabolites will be reported separately using their respective concentrations or normalized abundance values, according to the validated analytical method.
Time frame: Baseline, Weeks 12 and 24.
Changes in Serum Metabolite Profiles Assessed by Metabolomics
Changes from baseline in serum metabolite profiles assessed by metabolomics analysis. Prespecified serum metabolites will be identified and quantified where applicable. Individual metabolites will be reported separately using their respective concentrations or normalized abundance values, according to the validated analytical method.
Time frame: Baseline, Weeks 12 and 24.
Change in Fecal 3-Hydroxybutyric Acid Concentration from Baseline
Change from baseline in the concentration of 3-hydroxybutyric acid (β-hydroxybutyrate, BHB) in fecal samples. BHB will be measured using the prespecified laboratory assay. Results will be reported as concentration per unit of fecal sample using the validated assay's reporting units.
Time frame: Baseline, Weeks 12 and 24.
Change in Serum 3-Hydroxybutyric Acid Concentration from Baseline
Change from baseline in serum 3-hydroxybutyric acid (β-hydroxybutyrate, BHB) concentration. BHB will be measured using the prespecified laboratory assay. Results will be reported in the applicable concentration unit, such as mmol/L, according to the laboratory method.
Time frame: Baseline, Weeks 12 and 24.
Exploratory Analysis of Baseline Akkermansia Characteristics and Treatment Response
The association between baseline Akkermansia abundance, gut microbiota characteristics, metabolite profiles, and clinical response to Akkermansia supplementation will be explored.
Time frame: Baseline to Week 24
Correlation Analysis Between Gut Microbiota, Metabolites and Clinical Parameters
Exploratory correlation analyses will be performed to evaluate relationships among gut microbiota characteristics, metabolite changes, inflammatory markers, metabolic parameters, and clinical outcomes.
Time frame: Baseline, Week 12, and Week 24
Plan to share: No — Individual participant data will not be shared with other researchers. The study data will be used for the purposes specified in the protocol and analyzed by the study investigators.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital of Nanchang University